Bhagiradha Chemicals & Industries Ltd
Bhagiradha Chemicals & Industries is an Agro Chemical Company in India involved in the manufacturing of insecticides, fungicides, herbicides etc. It was Promoted by late Sri S. Koteswara Rao, a former scientist of Indian Institute of Chemical Technology, Hyderabad in the year 1993.[1][2]
- Market Cap ₹ 2,663 Cr.
- Current Price ₹ 205
- High / Low ₹ 331 / 198
- Stock P/E 201
- Book Value ₹ 53.2
- Dividend Yield 0.07 %
- ROCE 5.19 %
- ROE 2.53 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 3.86 times its book value
- Promoter holding is low: 19.6%
- Company has a low return on equity of 6.64% over last 3 years.
- Company might be capitalizing the interest cost
- Dividend payout has been low at 9.66% of profits over last 3 years
- Debtor days have increased from 111 to 144 days.
- Promoter holding has decreased over last 3 years: -3.92%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Fertilizers & Agrochemicals Pesticides & Agrochemicals
Part of BSE Allcap BSE Commodities
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 246 | 318 | 436 | 502 | 408 | 440 | 500 | |
| 229 | 271 | 367 | 425 | 365 | 404 | 457 | |
| Operating Profit | 17 | 47 | 68 | 77 | 43 | 37 | 44 |
| OPM % | 7% | 15% | 16% | 15% | 11% | 8% | 9% |
| 4 | 2 | 1 | 1 | 3 | 9 | 3 | |
| Interest | 5 | 8 | 9 | 5 | 8 | 7 | 12 |
| Depreciation | 7 | 8 | 9 | 10 | 11 | 14 | 16 |
| Profit before tax | 9 | 32 | 51 | 64 | 27 | 25 | 19 |
| Tax % | 27% | 27% | 30% | 29% | 32% | 45% | |
| 7 | 23 | 36 | 45 | 18 | 14 | 13 | |
| EPS in Rs | 0.63 | 2.27 | 3.48 | 4.34 | 1.75 | 1.07 | 1.02 |
| Dividend Payout % | -0% | -0% | 7% | 9% | 6% | 14% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 0% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 22% |
| 3 Years: | -27% |
| TTM: | -40% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 38% |
| 5 Years: | 44% |
| 3 Years: | 25% |
| 1 Year: | -30% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | 7% |
| Last Year: | 3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 10 | 10 | 13 | 13 |
| Reserves | 124 | 147 | 182 | 303 | 403 | 669 | 677 |
| 43 | 62 | 81 | 50 | 62 | 89 | 189 | |
| 50 | 55 | 71 | 83 | 101 | 162 | 161 | |
| Total Liabilities | 225 | 273 | 342 | 447 | 576 | 933 | 1,040 |
| 138 | 152 | 157 | 173 | 214 | 245 | 256 | |
| CWIP | 4 | 2 | 5 | 28 | 68 | 289 | 377 |
| Investments | -0 | -0 | -0 | -0 | 38 | -0 | -0 |
| 83 | 119 | 181 | 246 | 256 | 399 | 406 | |
| Total Assets | 225 | 273 | 342 | 447 | 576 | 933 | 1,040 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 48 | 4 | 7 | 14 | 34 | -53 | |
| -39 | -21 | -17 | -60 | -116 | -200 | |
| -9 | 15 | 12 | 46 | 88 | 272 | |
| Net Cash Flow | 0 | -2 | 2 | 1 | 7 | 19 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 17 | 68 | 81 | 94 | 96 | 144 |
| Inventory Days | 137 | 97 | 91 | 108 | 168 | 173 |
| Days Payable | 59 | 89 | 73 | 69 | 98 | 125 |
| Cash Conversion Cycle | 95 | 76 | 99 | 132 | 166 | 193 |
| Working Capital Days | -12 | 21 | 32 | 90 | 94 | 124 |
| ROCE % | 20% | 25% | 22% | 8% | 5% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 13 Feb
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
13 Feb - Investor 1x1/group meetings on 18 Feb 2026 with Dolat Capital in Mumbai; no UPSI.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
12 Feb - Investor Presentation for the quarter ended December 31, 2025
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
11 Feb - Newspaper Publication of Unaudited Financial Results for the quarter ended 31.12.2025
-
Announcement under Regulation 30 (LODR)-Retirement
10 Feb - B. Krishna Mohan Rao retires Feb 28, 2026; Ranjit Kumar Kilaru appointed CFO effective Mar 01, 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Product Portfolio (32 Active Ingredients)[1]
The company's product portfolio includes a wide range of insecticides, fungicides, herbicides, and specialty intermediaries
a. Insecticides: Chlorpyrifos, Diafenthiuron, Fipronil, Buprofezin, etc.
b. Fungicides: Azoxystrobin
c. Herbicides: Imazethapyr, Clodinafop-propargyl, Cloquintocet-mexyl
d. Specialty-intermediaries: R-HPPA, 2,6-Dichloroaniline, etc [2]